Home / Learn / Immunotherapy / Telemedicine & Virtual Navigation

Telemedicine & Virtual Navigation

The Latest Resources

  • Telehealth: Partner in Innovation
    By Jennie R. Crews, MD, MMM, FACP
    At ASCO 2018, Fabrice Denis, MD, PhD, presented data showing improved survival in lung cancer patients who tracked their post-treatment symptoms using patient-reported outcomes (PROs). However, during the discussion session, speakers acknowledged that current PROs do not capture symptoms specific to IO. This gap presents an opportunity to explore telehealth solutions that help providers and patients manage IO treatment.
  • Harnessing Real-Time, Real-World Data to Improve Care
    By Matthew R. Zibelman, MD

    As a genitourinary medical oncologist specializing in immunotherapy for kidney and bladder cancers, I am continually striving for more ways to connect with and learn from my patients. The emerging availability of immuno-oncology (IO) drugs for the conditions I treat, as well as many other cancer types, has generated tremendous excitement amongst patients and oncologists, but there still is so much we don’t know.

  • IO Patients in the Emergency Department
    By Junaid Razzak, MBBS, MD, PhD

    Emergency physicians are partners in providing care to your acutely ill patients. Since emergency physicians’ experience with and exposure to the novel immunotherapies is relatively limited, it is important that ED physicians and nurses are aware of the indications for these agents and informed on potential acute and chronic complications of immunotherapy for cancer. 

  • Managing Survivorship Care After Immunotherapy
    By Regina Jacob, MD, MSCE

    Survivorship care planning requires communication, care coordination, and education. Since immune-related adverse events are still being discovered, these discussions are even more imperative. 

From Oncology Issues

  •  Best Practices for Implementing Cancer Immunotherapy in the Community
    The Association of Community Cancer Centers (ACCC) recently hosted live continuing medical education (CME)-certified learning workshops at two community cancer programs to review current barriers to immunotherapy implementation in the community setting. During the workshops, an expert faculty panel engaged participants in discussion on the challenges that they may face as they integrate immunotherapy into their clinical practice, as well as practical solutions and strategies they can apply to overcome these barriers. This article summarizes the guidance and information provided by the faculty on the various issues raised during the workshop discussions.
  •  Highlights from ASCO 2018
    By Cary A. Presant, MD, FACP, FASCO
    ASCO 2018 offered a wealth of new data that will continue to transform clinical practice and cancer program development. Most important, implementation of the scientifi c advances we learned at ASCO 2018 will improve the length and quality of life of our cancer patients.
  •  Turning on the Light Switch
    By Ann McGreal, RN
    Discover how 2017 ACCC Innovator Award winner Advocate Medical Group developed and implemented an immunotherapy program, lessons learned, and tools created to educate staff and patients.
  •  Best of ASCO 2017
    Cary A. Presant, MD, FACP, FASCO
    ASCO 2017 was filled with new information and long lines as 39,000 oncologists worldwide came together to hear the latest advances in cancer care.
  •  Real-World Experiences in Immunotherapy Delivery
    The ACCC education project, “Real-World Experiences in Immunotherapy Delivery,” addresses some of the practical issues that cancer programs must navigate to provide immunotherapy safely and effectively in their own communities.
  •  Advancing Immuno-Oncology in the Community Setting
    Steven Powell, MD
    As cancer treatment evolves with the emergence of genomics, personalized therapies, and immunotherapies, care delivery must also transform.

Blog Posts